Compare BLNK & PMN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | BLNK | PMN |
|---|---|---|
| Founded | 2009 | 2004 |
| Country | United States | Canada |
| Employees | N/A | N/A |
| Industry | Industrial Specialties | Pharmaceuticals and Biotechnology |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 86.2M | 84.1M |
| IPO Year | 2008 | 2022 |
| Metric | BLNK | PMN |
|---|---|---|
| Price | $0.46 | $8.35 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 5 | 8 |
| Target Price | $1.63 | ★ $42.49 |
| AVG Volume (30 Days) | ★ 1.1M | 29.9K |
| Earning Date | 11-05-2026 | 11-11-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 61.22 | N/A |
| EPS | ★ N/A | N/A |
| Revenue | ★ $126,197,000.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | $13.70 | N/A |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $0.45 | $0.29 |
| 52 Week High | $2.15 | $27.40 |
| Indicator | BLNK | PMN |
|---|---|---|
| Relative Strength Index (RSI) | 32.44 | 27.67 |
| Support Level | N/A | $7.98 |
| Resistance Level | $0.62 | $8.75 |
| Average True Range (ATR) | 0.03 | 0.87 |
| MACD | -0.01 | -0.11 |
| Stochastic Oscillator | 2.74 | 6.78 |
Blink Charging Co is an owner, operator, and provider of electric vehicle (EV) charging services. The company offers both residential and commercial EV charging equipment, enabling EV drivers to easily recharge at various location types. The Blink's principal line of products and services is its Blink EV charging networks, Blink EV charging equipment, and other EV-related services. The Blink Network is a proprietary, cloud-based system that operates, maintains, and manages Blink charging stations and handles the associated charging data, back-end operations, and payment processing. The Blink Network provides fleets, property owners, managers, parking companies, and state and municipal entities, among other types of commercial customers, with cloud-based services.
ProMIS Neurosciences Inc is a clinical-stage biotechnology company focused on generating and developing antibody therapeutics selectively targeting toxic misfolded proteins in neurodegenerative diseases such as Alzheimers disease (AD), amyotrophic lateral sclerosis (ALS), and multiple system atrophy (MSA). The company applies its thermodynamic, computational discovery platform, ProMIS, and Collective Coordinates to predict novel targets known as Disease Specific Epitopes on the molecular surface of misfolded proteins. Compnies product candidates are PMN310, PMN267, and PMN442. Lead product candidate is PMN310, a monoclonal antibody designed to treat AD by selectively targeting toxic, misfolded oligomers of amyloid-beta. PMN267 is companies second lead product candidate targeting ALS.